Epstein—Barr (EB) virus membrane antigen (MA) glycoprotein (gp340) purified by a molecular weight-based technique has been subjected to biochemical analysis. Following treatment with glycosidases or tunicamycin during synthesis, the carbohydrate moiety was found to be made up of both O-linked and N-linked types and to constitute about 50% of the molecular mass. Digestion studies with neuraminidase and oligosaccharidase have indicated that the molecule is heavily sialated with most of the sialic acid located on the O-linked sugars. The high carbohydrate content of gp340 appears to confer resistance to proteolysis; thus, V8 protease was only effective at concentrations above 1 mg/ml when three large fragments of mol. wt. 330K, 190K and 160K were generated. Removal of sialic acid before V8 protease digestion did not alter this pattern nor affect the antigenicity of the digestion fragments. Antigenicity of the intact molecule was likewise unaffected by removal of sialic acid nor were the O-linked and N-linked carbohydrate moieties essential for this property. The binding of virus-neutralizing human sera and monoclonal antibody by gp340 from which either O-linked or N-linked sugars had been removed seems to indicate that the sites on the molecule that generate the neutralizing antibodies are present in the protein component. The significance of these results is discussed in relation to the development of a subunit vaccine against EB virus.
BrownW. R. A.,
BarclayA. N.,
SunderlandC. A.,
WilliamsA. F.1981; Identification of a glycophorin-like molecule at the cell surface of rat thymocytes. Nature, London 289:456–460
ClevelandD. W.,
FischerS. G.,
KirschnerM. W.,
LaemmliU. K.1977; Peptide mapping by limited proteolysis in sodium dodecyl sulphate and analysis by gel electrophoresis. Journal of Biological Chemisty 252:1102–1106
EdsonC. M.,
Thorley-LawsonD. A.1983; Synthesis and processing of the three major envelope glycoproteins of Epstein-Barr virus. Journal of Virology 46:547–556
EpsteinM. A.1979; Vaccine control of EB virus-associated tumors. In The Epstein-Barr Virus pp 440–448 Edited by
EpsteinM. A.,
AchongB. G.
Berlin, Heidelberg & New York: Springer-Verlag;
EpsteinM. A.,
MorganA. J.1983; Clinical consequences of Epstein-Barr virus infection and possible control by an antiviral vaccine. Clinical and Experimental Immunology 53:257–271
FranklinS. M.,
NorthJ. R.,
MorganA. J.,
EpsteinM. A.1981; Antigenic differences between the membrane antigen polypeptides determined by different EB virus isolates. Journal of General Virology 53:371–376
HoffmanG.,
LazarowitzS. G.,
HaywardS. D.1980; Monoclonal antibody against a 250, 000-dalton glycoprotein of Epstein-Barr virus identifies a membrane antigen and a neutralizing antigen. Proceedings of the National Academy of Sciences, U.S.A 77:2979–2983
MillerG.,
ShopeT.,
LiscoH.,
StittD.,
LipmanM.1972; Epstein-Barr virus: transformation, cytopathic changes, and viral antigens in squirrel monkey and marmoset leukocytes. Proceedings of the National Academy of Sciences, U.S.A. 69:383–387
MorganA. J.,
EpsteinM. A.,
NorthJ. R.1983a; Comparative immunogenicity studies on Epstein-Barr (EB) virus membrane antigen (MA) with novel adjuvants in mice, rabbits and cotton-top tamarins. Journal of Medical Virology (in press)
MorganA. J.,
NorthJ. R.,
EpsteinM. A.1983b; Purification and properties of the gp340 component of Epstein-Barr (EB) virus membrane antigen (MA) in an immunogenic form. Journal of General Virology 64:455–460
NorthJ. R.,
MorganA. J.,
EpsteinM. A.1980; Observations on the EB virus envelope and virus-determined membrane antigen (MA) polypeptides. International Journal of Cancer 26:231–240
NorthJ. R.,
MorganA. J.,
ThompsonJ. L.,
EpsteinM. A.1982a; Purified EB virus gp340 induces potent virusneutralizing antibodies when incorporated in liposomes. Proceedings of the National Academy of Sciences, U.S.A 79:7504–7508
SegrestJ. P.,
JacksonR. L.,
AndrewsE. P.,
MarchesiV. T.1971; Human erythrocyte membrane glycoprotein: a re-evaluation of the molecular weight as determined by SDS polyacrylamide gel electrophoresis. Biochemical and Biophysical Research Communications 44:390–395
StrnadB. C.,
NeubauerR. H.,
RabinH.,
MazurR. A.1979; Correlation between Epstein-Barr virus membrane antigen and three large cell surface glycoproteins. Journal of Virology 32:885–894
Thorley-LawsonD. A.,
GeilingerK.1980; Monoclonal antibodies against the major glycoprotein (gp350/220) of Epstein-Barr virus neutralize infectivity. Proceedings of the National Academy ofSciences, U.S.A. 77:5307–5311
Thorley-LawsonD. A.,
PoodryC. A.1982; Identification and isolation of the main component (gp350–gp220) of Epstein-Barr virus responsible for generating neutralizing antibodies in vivo. Journal of Virology 43:730–736